Fox Run Management’s ResMed RMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.94M Buy
+8,768
New +$1.91M 0.23% 88
2025
Q4
– Sell
-1,630
Closed -$446K – 1201
2025
Q3
$446K Buy
+1,630
New +$445K 0.07% 541
2025
Q1
– Sell
-3,950
Closed -$903K – 1177
2024
Q4
$903K Buy
+3,950
New +$951K 0.16% 194
2024
Q3
– Sell
-8,347
Closed -$1.6M – 1056
2024
Q2
$1.6M Buy
8,347
+4,408
+112% +$894K 0.3% 56
2024
Q1
$780K Buy
+3,939
New +$722K 0.17% 220
2023
Q3
– Sell
-3,035
Closed -$663K – 946
2023
Q2
$663K Buy
+3,035
New +$676K 0.19% 202
2023
Q1
– Sell
-3,148
Closed -$655K – 895
2022
Q4
$655K Buy
+3,148
New +$692K 0.26% 88
2022
Q1
– Sell
-2,083
Closed -$543K – 668
2021
Q4
$543K Buy
+2,083
New +$541K 0.32% 70
2021
Q1
– Sell
-1,026
Closed -$218K – 297
2020
Q4
$218K Buy
+1,026
New +$205K 0.44% 123
2018
Q3
– Sell
-5,370
Closed -$556K – 784
2018
Q2
$556K Buy
+5,370
New +$543K 0.18% 195
2017
Q4
– Sell
-6,900
Closed -$531K – 854
2017
Q3
$531K Buy
+6,900
New +$528K 0.15% 272
2017
Q2
– Sell
-7,900
Closed -$569K – 792
2017
Q1
$569K Buy
7,900
+1,300
+20% +$89.8K 0.23% 143
2016
Q4
$410K Buy
+6,600
New +$404K 0.22% 190

Other funds holding RMD

Fox Run Management's RMD Position: Q3 2026 in Review

Fox Run Management opened a new position in ResMed (RMD) in Q3 2026: 8,768 shares worth $1.94M. The stake represents 0.23% of the portfolio and ranks #88 among its holdings. This is a return to the name: Fox Run Management previously reported a position in RMD as recently as Q3 2025.

Fox Run Management first reported a position in RMD in Q4 2016 and has held it in 13 quarters since. 880 funds tracked by Wall St. Rank hold RMD as of Q3 2026.

  • Fox Run Management held 8,768 shares of ResMed worth $1.94M as of Q3 2026.
  • ResMed was a new Fox Run Management position in Q3 2026.
  • ResMed made up 0.23% of Fox Run Management's portfolio in Q3 2026, its #88 holding.
  • Fox Run Management first reported a position in ResMed in Q4 2016 and has held it in 13 quarters since.
  • 880 funds tracked by Wall St. Rank held ResMed as of Q3 2026.

Based on Fox Run Management's 13F filing for Q3 2026, filed 12 Nov 2026.